Anthera Pharmaceuticals Inc (NASDAQ:ANTH) Sellers Strengthened By 11.09% Their Shorts

May 16, 2018 - By Ashley Edward

Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) Corporate Logo

It was reported an increase on Anthera Pharmaceuticals Inc (NASDAQ:ANTH)’s shares shorted with 11.09%. FINRA announced in May ANTH’s total 2.14M shares shorted. The up change of 11.09% from 1.92M shares was reported. With Average volume 770,900, ANTH’s former position will take 3 days to recover.

The stock decreased 2.83% or $0.0088 during the last trading session, hitting $0.3026.Currently Anthera Pharmaceuticals, Inc. is downtrending after 90.50% change in last May 16, 2017. ANTH has also 270,082 shares volume. The stock underperformed the S&P500 by 102.05%.

Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs.The company has $7.08 million market cap. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of immunoglobulin A nephropathy.Currently it has negative earnings.

Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) Ratings Coverage

In total 3 analysts cover Anthera Pharmaceuticals (NASDAQ:ANTH). “Buy” rating has 1, “Sell” are 1, while 1 are “Hold”. 33% are bullish. 5 are the (NASDAQ:ANTH)’s analyst reports since January 22, 2018 according to StockzIntelligence Inc. On Monday, March 12 the company was downgraded by Piper Jaffray. On Monday, January 22 Piper Jaffray maintained the shares of ANTH in report with “Buy” rating. The company rating was maintained by Jefferies on Tuesday, March 6. On Tuesday, February 13 the rating was maintained by Jefferies with “Hold”.

Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.